Sleep Quality Improvements After MDMA‐Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder

Ponté, Linnae; Jerome, Lisa; Hamilton, Scott; Mithoefer, Michael C.; Yazar‐Klosinski, Berra; Vermetten, Eric; Feduccia, Allison A.

doi:10.1002/jts.22696

Cited by 19 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Systematic reviews [ 542 , 830 - 832 ] report a high rate of clinical response and remission and large effect size for reducing the symptoms of PTSD and depression. Improvements in Sheehan Disability Scale [ 813 ] and sleep quality [ 833 ] have also been reported. Study quality has been reported as moderate [ 542 , 830 ].…”

Section: Emerging and Novel Approaches To The Treatment Of Ptsdmentioning

confidence: 99%

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review

Burback

Brémault‐Phillips

Nijdam

et al. 2024

Self Cite

View full text Add to dashboard Cite

This narrative state-of-the-art review paper describes the progress in the understanding and treatment of Posttraumatic Stress Disorder (PTSD). Over the last four decades, the scientific landscape has matured, with many interdisciplinary contributions to understanding its diagnosis, etiology, and epidemiology. Advances in genetics, neurobiology, stress pathophysiology, and brain imaging have made it apparent that chronic PTSD is a systemic disorder with high allostatic load. The current state of treatment yields a wide variety of pharmacological and psychotherapeutic approaches, of which many are evidence-based. However, the myriad challenges inherent in the disorder, such as individual and systemic barriers to treatment outcome, comorbidity, emotional dysregulation, suicidality, dissociation, substance use, and trauma-related guilt and shame often render treatment response suboptimal. These challenges are discussed as drivers for emerging novel treatment approaches, including early interventions in the Golden Hours, pharmacological and psychotherapeutic interventions, medication augmentation interventions, the use of psychedelics, as well as interventions targeting the brain and nervous system. All of this aims to improve symptom relief and clinical outcomes. Finally, a phase orientation to treatment is recognized as a tool to strategize treatment of the disorder, and position interventions in step with the progression of the pathophysiology. Revisions to guidelines and systems of care will be needed to incorporate innovative treatments as evidence emerges and they become mainstream. This generation is well-positioned to address the devastating and often chronic disabling impact of traumatic stress events through holistic, cutting-edge clinical efforts and interdisciplinary research.

show abstract

Section: Emerging and Novel Approaches To The Treatment Of Ptsdmentioning

confidence: 99%

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review

Burback

Brémault‐Phillips

Nijdam

et al. 2024

Self Cite

View full text Add to dashboard Cite

show abstract

“…Im Rahmen der Auswertung der Phase-III-Studie zur Behandlung der PTBS zeigte sich eine signifikante Abnahme von Symptomen einer Essstörung in der Experimentalgruppe im Vergleich zur Kontrollgruppe 18 . Weiterhin wurden signifikant positive Ergebnisse im Hinblick auf Schlafqualität 19 , Alkoholkonsum 20 und chronische Schmerzen 21 als Begleitsymptome der PTBS beobachtet. Beim Drogenkonsum konnte kein signifikanter Gruppenunterschied beobachtet werden 20 .…”

Section: Aktueller Forschungsstandunclassified

MDMA-gestützte Therapie

Bechtold,

Repantis

2024

Nervenheilkunde

View full text Add to dashboard Cite

ZUSAMMENFASSUNGNeben den klassischen Psychedelika, z. B. Psilocybin, werden wieder vermehrt andere Substanzen wie 3,4-Methylendioxy-N-methylamphetamin (MDMA) erforscht. Das Entaktogen („innerlich berührend“) ist in den USA nur noch wenige Schritte von einer möglichen Zulassung zur Behandlung der posttraumatischen Belastungsstörung entfernt. Dieser Artikel soll einen Überblick über die Wirkung, den Einsatz im therapeutischen Setting sowie den Forschungsstand geben. Hierbei sollen insbesondere Sicherheitsaspekte der MDMA-gestützten Therapie beleuchtet werden. Zuletzt folgt ein Ausblick auf eine mögliche Zulassung und damit einhergehende offene Fragen, wie beispielsweise die Umsetzung in der klinischen Praxis. Auch die Notwendigkeit weiterer Studien wird diskutiert.

show abstract

“…Based on the pooled results of similar trials, the Food and Drug Administration (FDA) approved MDMA-assisted therapy as a break-through treatment for PTSD ( 6 ). Studies are ongoing, investigating both the overall efficacy of psychedelics in the treatment of PTSD as well as their effect on specific symptoms such as disturbed sleep and persistent nightmares ( 62 ).…”

Section: Ptsd Treatmentmentioning

confidence: 99%

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Sottile

Vida

2022

Front. Psychiatry

View full text Add to dashboard Cite

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease. 3,4-Methylenedioxy-methamphetamine (MDMA), like classic psychedelics such as psilocybin, have been used to enhance the efficacy of psychotherapy almost since their discovery, but due to their perceived potential for abuse and inclusion on USFDA (United States Food and Drug Administration) schedule 1, research into the mechanism by which they produce improvements in PTSD symptomology has been limited. Nevertheless, several compelling rationales have been explored, with the pro-social effects of MDMA thought to enhance therapeutic alliance and thus facilitate therapist-assisted trauma processing. This may be insufficient to fully explain the efficacy of MDMA in the treatment of psychiatric illness. Molecular mechanisms such as the MDMA mediated increase of brain-derived neurotrophic factor (BDNF) availability in the fear memory learning pathways combined with MDMA's pro-social effects may provide a more nuanced explanation for the therapeutic actions of MDMA.

show abstract

Sleep Quality Improvements After MDMA‐Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder

Cited by 19 publications

References 67 publications

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review

Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review

MDMA-gestützte Therapie

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Contact Info

Product

Resources

About